Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children - Yukon-Kuskokwim Delta Region, Alaska, October 2023-June 2024.

IF 25.4 1区医学 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

MMWR. Morbidity and mortality weekly report Pub Date : 2024-11-14 DOI:10.15585/mmwr.mm7345a1

Brian Lefferts, Sara Bressler, James W Keck, Christine Desnoyers, Ellen Hodges, Gerald January, Kristina Morris, Leslie Herrmann, Rosalyn Singleton, Sarah Aho, Julia Rogers, Katherine Newell, Elizabeth Ohlsen, Ruth Link-Gelles, Fatimah S Dawood, Dana Bruden, Marc Fischer, Joseph Klejka, Heather M Scobie

{"title":"Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children - Yukon-Kuskokwim Delta Region, Alaska, October 2023-June 2024.","authors":"Brian Lefferts, Sara Bressler, James W Keck, Christine Desnoyers, Ellen Hodges, Gerald January, Kristina Morris, Leslie Herrmann, Rosalyn Singleton, Sarah Aho, Julia Rogers, Katherine Newell, Elizabeth Ohlsen, Ruth Link-Gelles, Fatimah S Dawood, Dana Bruden, Marc Fischer, Joseph Klejka, Heather M Scobie","doi":"10.15585/mmwr.mm7345a1","DOIUrl":null,"url":null,"abstract":"<p><p>Respiratory syncytial virus (RSV) is a leading cause of hospitalization among young children. Historically, American Indian and Alaska Native (AI/AN) children have experienced high rates of RSV-associated hospitalization. In August 2023, a preventive monoclonal antibody (nirsevimab) was recommended for all infants aged <8 months (born during or entering their first RSV season) and for children aged 8-19 months (entering their second RSV season) who have increased risk for severe RSV illness, including all AI/AN children. This evaluation in Alaska's Yukon-Kuskokwim Delta region estimated nirsevimab effectiveness among AI/AN children in their first or second RSV seasons during 2023-2024. Among 472 children with medically attended acute respiratory illness (ARI), 48% overall had received nirsevimab ≥7 days earlier (median = 91 days before the ARI-related visit). For children in their first RSV season (292), nirsevimab effectiveness was 76% (95% CI = 42%-90%) against medically attended RSV illness and 89% (95% CI = 32%-98%) against RSV hospitalization. For children in their second RSV season (180), effectiveness against medically attended RSV illness was 88% (95% CI = 48%-97%). Nirsevimab is effective for preventing severe RSV illness among infants entering their first RSV season and children entering their second season with increased risk for severe RSV, including all AI/AN children.</p>","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"73 45","pages":"1015-1021"},"PeriodicalIF":25.4000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MMWR. Morbidity and mortality weekly report","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15585/mmwr.mm7345a1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Respiratory syncytial virus (RSV) is a leading cause of hospitalization among young children. Historically, American Indian and Alaska Native (AI/AN) children have experienced high rates of RSV-associated hospitalization. In August 2023, a preventive monoclonal antibody (nirsevimab) was recommended for all infants aged <8 months (born during or entering their first RSV season) and for children aged 8-19 months (entering their second RSV season) who have increased risk for severe RSV illness, including all AI/AN children. This evaluation in Alaska's Yukon-Kuskokwim Delta region estimated nirsevimab effectiveness among AI/AN children in their first or second RSV seasons during 2023-2024. Among 472 children with medically attended acute respiratory illness (ARI), 48% overall had received nirsevimab ≥7 days earlier (median = 91 days before the ARI-related visit). For children in their first RSV season (292), nirsevimab effectiveness was 76% (95% CI = 42%-90%) against medically attended RSV illness and 89% (95% CI = 32%-98%) against RSV hospitalization. For children in their second RSV season (180), effectiveness against medically attended RSV illness was 88% (95% CI = 48%-97%). Nirsevimab is effective for preventing severe RSV illness among infants entering their first RSV season and children entering their second season with increased risk for severe RSV, including all AI/AN children.

查看原文本刊更多论文

2023 年 10 月至 2024 年 6 月期间，Nirsevimab 对阿拉斯加原住民儿童呼吸道合胞病毒疾病和住院治疗的疗效 - 阿拉斯加州育空-库斯科金三角洲地区。

呼吸道合胞病毒（RSV）是导致幼儿住院治疗的主要原因。从历史上看，美国印第安人和阿拉斯加原住民（AI/AN）儿童的 RSV 相关住院率一直很高。2023 年 8 月，推荐为所有年龄在 5 岁以下的婴儿使用预防性单克隆抗体（nirsevimab）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

MMWR. Morbidity and mortality weekly report PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH -

CiteScore

65.40

自引率

0.90%

发文量

309

期刊介绍： The Morbidity and Mortality Weekly Report (MMWR ) series is prepared by the Centers for Disease Control and Prevention (CDC). Often called “the voice of CDC,” the MMWR series is the agency’s primary vehicle for scientific publication of timely, reliable, authoritative, accurate, objective, and useful public health information and recommendations. MMWR readership predominantly consists of physicians, nurses, public health practitioners, epidemiologists and other scientists, researchers, educators, and laboratorians.